DOI: 10.1002/advs.202302717 ISSN:

TCAF2 in Pericytes Promotes Colorectal Cancer Liver Metastasis via Inhibiting Cold‐Sensing TRPM8 Channel

Xiaobo Li, Qi Qi, Yong Li, Qun Miao, Wenqian Yin, Jinghua Pan, Zhan Zhao, Xiaoying Chen, Fan Yang, Xiaofeng Zhou, Maohua Huang, Chenran Wang, Lijuan Deng, Dandan Huang, Ming Qi, Shuran Fan, Yiran Zhang, Shenghui Qiu, Weiqing Deng, Tongzheng Liu, Minfeng Chen, Wencai Ye, Dongmei Zhang
  • General Physics and Astronomy
  • General Engineering
  • Biochemistry, Genetics and Molecular Biology (miscellaneous)
  • General Materials Science
  • General Chemical Engineering
  • Medicine (miscellaneous)

Abstract

Hematogenous metastasis is the main approach for colorectal cancer liver metastasis (CRCLM). However, as the gatekeepers in the tumor vessels, the role of TPCs in hematogenous metastasis remains largely unknown, which may be attributed to the lack of specific biomarkers for TPC isolation. Here, microdissection combined with a pericyte medium‐based approach is developed to obtain TPCs from CRC patients. Proteomic analysis reveals that TRP channel‐associated factor 2 (TCAF2), a partner protein of the transient receptor potential cation channel subfamily M member 8 (TRPM8), is overexpressed in TPCs from patients with CRCLM. TCAF2 in TPCs is correlated with liver metastasis, short overall survival, and disease‐free survival in CRC patients. Gain‐ and loss‐of‐function experiments validate that TCAF2 in TPCs promotes tumor cell motility, epithelial‐mesenchymal transition (EMT), and CRCLM, which is attenuated in pericyte‐conditional Tcaf2‐knockout mice. Mechanistically, TCAF2 inhibits the expression and activity of TRPM8, leading to Wnt5a secretion in TPCs, which facilitates EMT via the activation of the STAT3 signaling pathway in tumor cells. Menthol, a TRPM8 agonist, significantly suppresses Wnt5a secretion in TPCs and CRCLM. This study reveals the previously unidentified pro‐metastatic effects of TPCs from the perspective of cold‐sensory receptors, providing a promising diagnostic biomarker and therapeutic target for CRCLM.

More from our Archive